Immunization

Phreesia Joins Call to Action to Improve Adult Vaccination Rates

Retrieved on: 
Tuesday, January 23, 2024

Phreesia, a leader in patient intake, outreach and activation, is pleased to announce that it has joined the National Adult and Influenza Immunization Summit’s Call to Action for Adult Immunizations campaign to improve adult vaccination rates.

Key Points: 
  • Phreesia, a leader in patient intake, outreach and activation, is pleased to announce that it has joined the National Adult and Influenza Immunization Summit’s Call to Action for Adult Immunizations campaign to improve adult vaccination rates.
  • More than three in four adults are missing routinely recommended vaccines and, due to preventive care put on hold during the COVID-19 pandemic, low vaccination rates have worsened.
  • The mission of the campaign is to encourage healthcare providers to take action to improve the implementation of adult vaccination recommendations to protect adults from preventable illness, disability and death.
  • Within the last few years, Phreesia has delivered over 20.7 million messages to adults to encourage conversations with care teams about recommended vaccines.

The Astellas Global Health Foundation Provides $2.6 Million in New Funding to Address Urgent Health Needs in Africa, South America, and the Middle East

Retrieved on: 
Thursday, January 25, 2024

The selected organizations -- International Medical Corps, PATH, and Plan International -- are expected to use the Foundation grants to impact nearly 750,000 lives combined over the next three years. This latest funding, in addition to active grants in progress with Amref Health Africa and AMPATH Kenya, reinforces the Foundation's objective to help high-need populations within low- and middle-income countries where Astellas does not have a business presence.

Key Points: 
  • Efforts will include strengthening healthcare infrastructure and building resilience in 10 vulnerable and hard-to-reach Yemeni communities (projected impact: more than 60,000 lives).
  • In 2020 and 2021, the Foundation supported the organization's important work fighting COVID-19 in Nigeria and malaria and dengue in Venezuela.
  • PATH: The Foundation has awarded a three-year grant of more than $1.6 million to help PATH address HIV/AIDS and tuberculosis (TB) healthcare delivery barriers in Kenya.
  • The grant will also see supply chain strengthening activities to ensure the availability of high-quality commodities and tools for community health units.

New OmniSYS XiFin Pharmacy Solutions CareALERTS™ Data Demonstrate Critical Role Pharmacists Play as Healthcare Providers

Retrieved on: 
Friday, January 12, 2024

OmniSYS, the pharmacy division of XiFin, Inc., announced its 2023 end-of-year CareALERTS™ data, demonstrating how pharmacists as providers are closing healthcare gaps at the point of care.

Key Points: 
  • OmniSYS, the pharmacy division of XiFin, Inc., announced its 2023 end-of-year CareALERTS™ data, demonstrating how pharmacists as providers are closing healthcare gaps at the point of care.
  • OmniSYS released this data on National Pharmacist Day to celebrate pharmacists and urges all U.S. states to recognize pharmacists as providers of clinical services who can help address physician shortages and improve healthcare access for the nation’s most vulnerable and underserved communities.
  • "We deeply appreciate the vital role pharmacists play in enhancing the well-being of Americans, especially seniors facing healthcare challenges.
  • “The role of the pharmacy continues to evolve as millions of Americans rely on pharmacists as first-line providers of healthcare,” said XiFin chief pharmacy officer David Pope, PharmD, CDE.

United States Laboratory Industry Report 2023: Analysis of New Services, Technological Innovations, Sustainable Practices, and Impact of Regulatory Changes - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 9, 2024

The 2023 Laboratory Market Report analyzes new laboratory services, technological innovations, sustainable practices in clinical laboratories, and the impact of regulatory changes on the overall market.

Key Points: 
  • The 2023 Laboratory Market Report analyzes new laboratory services, technological innovations, sustainable practices in clinical laboratories, and the impact of regulatory changes on the overall market.
  • The U.S. laboratory market was valued at $93 billion in 2022, a 17% decrease from $112.1 billion in 2021 when COVID-19 testing drove market growth.
  • Post-pandemic, the major factors impacting the laboratory market include increased demand for personalized medicine, the aging population, the high rate of chronic diseases, and laboratory innovations.
  • Technological advancements are helping laboratories enable remote work, alleviate inventory management challenges, and cut waste to support sustainability goals.

Omniose Announces Scientific Collaboration With AstraZeneca to Research Vaccines for Serious Bacterial Diseases

Retrieved on: 
Friday, January 5, 2024

Omniose, a preclinical biotechnology company, today announced an exclusive collaboration agreement with AstraZeneca to research potential vaccines for bacterial pathogens in AstraZeneca’s early Vaccines & Immune Therapies pipeline.

Key Points: 
  • Omniose, a preclinical biotechnology company, today announced an exclusive collaboration agreement with AstraZeneca to research potential vaccines for bacterial pathogens in AstraZeneca’s early Vaccines & Immune Therapies pipeline.
  • Under the terms of the agreement, AstraZeneca will have exclusive rights to Omniose’s proprietary bioconjugation platform for up to three years, which allows for the development of high-quality vaccines against a range of bacterial pathogens, including multidrug-resistant “superbugs” previously intractable by other methods.
  • Conjugate vaccines are an effective form of immunization however, their use is limited due to the complex chemical process of attaching bacterial polysaccharides to engineered carrier proteins.
  • As part of our ambition to provide long-lasting immunity to millions of people, we are excited to enter into this scientific collaboration with Omniose to explore the role of this novel bioconjugate platform in developing vaccines for bacterial pathogens.”

Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise

Retrieved on: 
Thursday, January 4, 2024

-- Enrollment in Ongoing VAX-24 Infant Phase 2 Study Continues to Progress; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 --

Key Points: 
  • Vaxcyte’s carrier-sparing PCV franchise candidates, including VAX-24, a 24-valent PCV proceeding to Phase 3, and VAX-31, the Company’s next-generation 31-valent PCV, are being studied for the prevention of invasive pneumococcal disease (IPD).
  • The VAX-24 Phase 2 infant study continues to enroll participants in the second and final stage of the study.
  • This is a randomized, observer-blind, dose-finding two-stage clinical study evaluating the safety, tolerability and immunogenicity of VAX-24 in healthy infants.
  • Topline safety, tolerability and immunogenicity data from the ongoing adult Phase 1/2 study in the third quarter of 2024.

GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox

Retrieved on: 
Tuesday, December 19, 2023

The amendment expands GeoVax’s commercial license to include Mpox and smallpox as additional indications.

Key Points: 
  • The amendment expands GeoVax’s commercial license to include Mpox and smallpox as additional indications.
  • Modified Vaccinia Ankara (MVA) is the vaccine currently used and stockpiled in the U.S. Strategic National Stockpile for immunization against the Mpox and smallpox viruses.
  • The addition of the Mpox and smallpox indications to our NIAID License Agreement complements GeoVax’s license agreement with COH for GEO-CM04S1, which we also recently amended to obtain development and commercialization rights against orthopoxviruses in addition to SARS-CoV-2.
  • For those regions/populations where Mpox and/or smallpox may be of a concern, we believe our COVID-19 vaccine will be a better choice.”

GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress

Retrieved on: 
Thursday, November 30, 2023

ATLANTA, GA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of data from recent preclinical studies of its vaccine candidates against Marburg virus and Sudan virus.

Key Points: 
  • The data were presented during the World Vaccine Congress, West Coast conference, being held in Santa Clara, CA from November 27-30, 2023.
  • Mark Newman, Ph.D., GeoVax Chief Scientific Officer, commented, “We are highly encouraged by the results of these studies of our MARV vaccine candidate.
  • The vaccine induced immune responses were characterized by MARV-specific binding and neutralizing antibodies as well as other effector functions like antibody-dependent phagocytosis.
  • The Angola strain is the most virulent strain of MARV characterized by a fatality rate of up to 90% in humans.

Uvax Bio Receives Approval to Initiate a Phase 1 Clinical Trial of Novel HIV-1 Protein Nanoparticle Vaccine Candidates in Australia

Retrieved on: 
Tuesday, December 19, 2023

Uvax Bio, LLC , a privately held, clinical-stage vaccine company, today announced acknowledgement from Australian Therapeutic Goods Administration and approval from the Human Research Ethics Committee (HREC) to conduct a Phase 1 study of Uvax Bio's HIV-1 vaccine candidates in healthy volunteers in Australia.

Key Points: 
  • Uvax Bio, LLC , a privately held, clinical-stage vaccine company, today announced acknowledgement from Australian Therapeutic Goods Administration and approval from the Human Research Ethics Committee (HREC) to conduct a Phase 1 study of Uvax Bio's HIV-1 vaccine candidates in healthy volunteers in Australia.
  • Uvax Bio will work with their Australia-based clinical research partners Avance Clinical and the Nucleus Network study site to initiate this study in January 2024.
  • In a second preclinical immunogenicity study, immunization with Uvax Bio’s HIV-1 vaccine candidates elicited robust neutralizing antibody responses against the vaccine-matched virus in 99% of the animals.
  • “Our clinical team will immediately begin the preparation to initiate this trial in January 2024.”

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

Retrieved on: 
Tuesday, November 14, 2023

CAMBRIDGE, Massachusetts, Nov. 14, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • “The third quarter was marked by significant progress across both our clinical and corporate initiatives,” said Gail Farfel, Ph.D., Chief Executive Officer of ProMIS Neurosciences.
  • These results replicated biomarker findings from the CLARITY-AD trial of lecanemab, which also predominantly targets soluble amyloid beta oligomers.
  • In July 2023, the Company presented preclinical data from mouse vaccination studies at AAIC 2023.
  • Net loss was $2.4 million for the quarter ended September 30, 2023, compared to a net loss of $6.0 million for the same period in 2022.